skip-to-main

Great Britain

- Spikevax bivalent Original/Omicron BA.1 ▼(50 micrograms/50 micrograms)/mL dispersion for injection

A Conditional Marketing Authorisation (CMA) has has been granted in the UK for Spikevax bivalent Original/Omicron as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.


Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Nov 04, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 26, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 12, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 09, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 07, 2022

- Spikevax▼ (previously COVID-19 Vaccine Moderna)

A Conditional Marketing Authorisation (CMA) has been granted in the UK for Spikevax for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 27, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 07, 2022

Northern Ireland

- Spikevax bivalent Original/Omicron BA.4-5 ▼(50 micrograms/50 micrograms)/mL dispersion for injection

A Conditional Marketing Authorisation has been granted in the EU for Spikevax bivalent Original/Omicron BA.4-5 for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

- Spikevax bivalent Original/Omicron BA.1 ▼(50 micrograms/50 micrograms)/mL dispersion for injection

A Conditional Marketing Authorisation has been granted in the EU for Spikevax bivalent Original/Omicron BA.1 for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID‑19.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 29, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 21, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 12, 2022

- Spikevax▼ (previously COVID-19 Vaccine Moderna)

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 27, 2022

Contact Moderna